Integrins play a critical role in the progression of prostate cancer and its bone metastases. We investigated the use of the pan-αv integrin inhibitor abituzumab in chemotherapy-naïve patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PERSEUS (NCT01360840) was a randomized, double-blind phase II study. Men with pathologically confirmed prostate cancer and radiologic progression of bone lesions in the 28 days prior to randomization were assigned to receive abituzumab 750 mg or 1,500 mg or placebo (1:1:1) every 3 weeks in combination with luteinizing hormone-releasing hormone agonist/antagonist therapy. The primary endpoint was progression-free survival (PFS).
The intent-to-treat population comprised 180 patients, 60 in each arm. The primary endpoint of PFS was not significantly different with abituzumab-based therapy compared to placebo (abituzumab 750 mg, 3. 4 months, HR = 0. 89 [0. 57-1. 39]; abituzumab 1,500 mg, 4. 3 months, HR = 0. 81 [0. 52-1. 26]; placebo, 3. 3 months), but the cumulative incidence of bone lesion progression was lower with abituzumab than with placebo for up to 24 months (cumulative incidence 23. 6% versus 41. 1% at 6 months, 26. 1% versus 45. 4% at 12 months). Two partial tumor responses were observed (1 abituzumab 1,500 mg and 1 placebo). Approximately 85-90% of patients experienced at least one treatment-emergent adverse event (TEAE) in the different arms, but the incidences of serious TEAEs and TEAEs with fatal outcome were similar in the three arms.
Although PFS was not significantly extended, abituzumab appears to have specific activity in prostate cancer-associated bone lesions that warrants further investigation.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Feb 02 [Epub ahead of print]
Maha Hussain, Sylvestre Le Moulec, Claude Gimmi, Rolf Bruns, Josef Straub, Kurt Miller
Hematology/Oncology, University of Michigan unit 981 INSERM, Institut Gustave Roussy. , Department of Clinical Oncology, Merck KGaA. , Department of Biostatistics, Merck KGaA. , Department of Clinical Biomarkers, Merck KGaA. , Urology, Charité - Universitätsmedizin Berlin.